Difluprednate ophthalmic

Drug Profile

Difluprednate ophthalmic

Alternative Names: Durezol; SJE-2079; ST-601

Latest Information Update: 05 Aug 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Senju Pharmaceutical
  • Developer Alcon; Senju Pharmaceutical; Sirion Therapeutics
  • Class Anti-inflammatories; Fluorinated steroids; Pregnadienetriols
  • Mechanism of Action Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ocular inflammation; Ocular pain; Uveitis
  • Phase II Diabetic macular oedema
  • No development reported Dry eyes

Most Recent Events

  • 28 Jul 2016 Senju Pharmaceutical completes a phase II trial for Diabetic macular oedema in Japan (UMIN000011873)
  • 03 Aug 2015 Difluprednate ophthalmic is still in phase II trials for Diabetic macular oedema in Japan
  • 07 Oct 2013 No development reported - Phase-II for Dry eyes in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top